In the wake of CMS releasing the first ten drugs that would be subject to price negotiations, Politico interviewed CAHC’s Joel White about the drugs chosen:
Joel White, president of the Council for Affordable Health Coverage and a former GOP Hill aide, suggested the CMS decision was political rather than scientific.
“Someone decided that, ‘hey, we need to do more on the insulin side of things,’” he said. “It’s a byproduct of a political decision-making process.”